MEPSEVII™ (vestronidase alfa-vjbk) should be administered under the supervision of a health care professional with the capability to manage anaphylaxis

 

MEPSEVII recommended dosage overview

  • Approximately 4-hour intravenous drip
  • Administer by intravenous infusion every 2 weeks
  • Infuse 2.5% of the total volume over the first hour
  • After the first hour, increase the infusion rate as tolerated in order to complete infusion over the following 3 hours
  • Premedication with a nonsedating antihistamine with or without an antipyretic is recommended 30 to 60 minutes prior to the start of infusion, for patient comfort

 

Supplies needed

  • MEPSEVII (vestronidase alfa-vjbk) 10-mg/5-mL single-dose vials
  • 0.9% Sodium Chloride Injection, USP
  • Infusion bag
  • 18-gauge needle
  • An infusion set equipped with an in-line, low-protein binding 0.2-micron filter
Image
 

MEPSEVII™ (vestronidase alfa-vjbk) should be administered under the supervision of a health care professional with the capability to manage anaphylaxis


MEPSEVII recommended dosage overview

  • Approximately 4-hour intravenous drip

  • Administer by intravenous infusion every 2 weeks

  • Infuse 2.5% of the total volume over the first hour

  • After the first hour, increase the infusion rate as tolerated in order to complete infusion over the following 3 hours

  • Premedication with a nonsedating antihistamine with or without an antipyretic is recommended 30 to 60 minutes prior to the start of infusion, for patient comfort

Supplies needed

  • MEPSEVII (vestronidase alfa-vjbk) 10-mg/5-mL single-dose vials

  • 0.9% Sodium Chloride Injection, USP

  • Infusion bag

  • 18-gauge needle

  • An infusion set equipped with an in-line, low-protein binding 0.2-micron filter
Image

Calculating the dose

  • Weigh the patient to determine the number of vials to be diluted based on the patient’s actual weight and the recommended dose of 4 mg/kg

  • Round to the next whole vial to determine the final total volume and number of vials needed based on the patient's weight

  • The final solution will be a 1:1 dilution of MEPSEVII with 0.9% Sodium Chloride Injection, USP
Image
 

Calculating the dose

  • Weigh the patient to determine the number of vials to be diluted based on the patient’s actual weight and the recommended dose of 4 mg/kg

  • Round to the next whole vial to determine the final total volume and number of vials needed based on the patient's weight

  • The final solution will be a 1:1 dilution of MEPSEVII with 0.9% Sodium Chloride Injection, USP
Image

INDICATION
MEPSEVII is a recombinant human lysosomal beta glucuronidase indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).

Limitations of Use
The effect of MEPSEVII on the central nervous system manifestations of MPS VII has not been determined.

BOXED WARNING AND ADDITIONAL IMPORTANT SAFETY INFORMATION

WARNING: ANAPHYLAXIS

  • Anaphylaxis has occurred with MEPSEVII administration, as early as the first dose, therefore appropriate medical support should be readily available when MEPSEVII is administered.
  • Closely observe patients during and for 60 minutes after MEPSEVII infusion.
  • Immediately discontinue the MEPSEVII infusion if the patient experiences anaphylaxis.
  • Anaphylaxis to MEPSEVII was reported in 2 of 20 patients in the clinical program. The two patients with anaphylaxis to MEPSEVII during the clinical trials had one occurrence each and tolerated subsequent infusions of MEPSEVII, without recurrence.
  • Consider the risks and benefits of re-administering MEPSEVII following anaphylaxis.
  • Manifestations included respiratory distress, cyanosis, decreased oxygen saturation, and hypotension.
  • Prior to discharge, inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care if symptoms occur.

Adverse Reactions

  • In a clinical trial, the most common adverse reactions occurring with MEPSEVII treatment included infusion site extravasation, diarrhea, rash, anaphylaxis, infusion site swelling, peripheral swelling, and pruritus.
  • One patient experienced a febrile convulsion during MEPSEVII treatment. The patient subsequently was re-challenged without recurrence and continued on treatment.

Use in Specific Populations

  • There are no available data on MEPSEVII use in pregnant women to determine a drug-associated risk of adverse developmental outcomes.
  • There are no data on the presence of MEPSEVII in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for MEPSEVII and any potential adverse effects on the breastfed infant from MEPSEVII or from the underlying maternal condition.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Ultragenyx at 1-888-756-8657.
Please see full Prescribing Information, including the BOXED WARNING, for a complete discussion of the risks associated with MEPSEVII.